MAP0004, a novel orally inhaled formulation of dihydroergotamine currently under development, may be effective in treating a broad spectrum of migraine, according to 2 phase 3 studies presented here September 12 at the 14th Congress of the International Headache Society & the 51st Annual Scientific Meeting of the American Headache Society.
Novel inhaled formulation of dihydroergotamine effective for a broad spectrum of migraine: